Amarin Co. plc (NASDAQ:AMRN) Shares Sold by Raymond James Financial Services Advisors Inc.

Raymond James Financial Services Advisors Inc. cut its position in shares of Amarin Co. plc (NASDAQ:AMRN) by 3.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 626,346 shares of the biopharmaceutical company’s stock after selling 22,806 shares during the quarter. Raymond James Financial Services Advisors Inc. owned 0.16% of Amarin worth $545,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of the company. Creative Planning increased its position in shares of Amarin by 66.4% during the 2nd quarter. Creative Planning now owns 17,285 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 6,900 shares during the period. UBS Group AG increased its position in shares of Amarin by 0.8% during the 2nd quarter. UBS Group AG now owns 887,084 shares of the biopharmaceutical company’s stock valued at $1,322,000 after purchasing an additional 7,003 shares during the period. Lido Advisors LLC boosted its stake in shares of Amarin by 23.7% during the 1st quarter. Lido Advisors LLC now owns 41,773 shares of the biopharmaceutical company’s stock worth $63,000 after acquiring an additional 8,000 shares in the last quarter. Bank of Montreal Can boosted its stake in shares of Amarin by 39.1% during the 2nd quarter. Bank of Montreal Can now owns 28,693 shares of the biopharmaceutical company’s stock worth $56,000 after acquiring an additional 8,068 shares in the last quarter. Finally, Commonwealth Equity Services LLC boosted its stake in shares of Amarin by 4.4% during the 1st quarter. Commonwealth Equity Services LLC now owns 198,854 shares of the biopharmaceutical company’s stock worth $298,000 after acquiring an additional 8,300 shares in the last quarter. 22.25% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of Amarin in a research note on Friday, January 12th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $1.08.

Amarin Stock Down 4.9 %

AMRN opened at $0.87 on Friday. The firm has a market cap of $358.02 million, a PE ratio of -6.23 and a beta of 1.98. The business has a fifty day simple moving average of $1.01 and a 200-day simple moving average of $0.93. Amarin Co. plc has a fifty-two week low of $0.65 and a fifty-two week high of $1.49.

Amarin (NASDAQ:AMRN) last issued its earnings results on Thursday, February 29th. The biopharmaceutical company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.04. The business had revenue of $74.71 million during the quarter, compared to analysts’ expectations of $72.46 million. Amarin had a negative return on equity of 10.47% and a negative net margin of 19.26%. On average, equities research analysts anticipate that Amarin Co. plc will post -0.14 EPS for the current fiscal year.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.